193 related articles for article (PubMed ID: 31743739)
1. Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
Zheng Y; Obeng S; Reinecke BA; Chen C; Phansalkar PS; Walentiny DM; Gerk PM; Liu-Chen LY; Selley DE; Beardsley PM; Zhang Y
Eur J Pharmacol; 2019 Dec; 865():172812. PubMed ID: 31743739
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.
Zhang Y; Braithwaite A; Yuan Y; Streicher JM; Bilsky EJ
Eur J Pharmacol; 2014 Aug; 736():124-30. PubMed ID: 24815322
[TBL] [Abstract][Full Text] [Related]
3. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
[TBL] [Abstract][Full Text] [Related]
5. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
Obeng S; Yuan Y; Jali A; Selley DE; Zhang Y
Eur J Pharmacol; 2018 May; 827():32-40. PubMed ID: 29530590
[TBL] [Abstract][Full Text] [Related]
7. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
[TBL] [Abstract][Full Text] [Related]
8. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
9. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
10. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
14. The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation.
Petraschka M; Li S; Gilbert TL; Westenbroek RE; Bruchas MR; Schreiber S; Lowe J; Low MJ; Pintar JE; Chavkin C
Neuroscience; 2007 Jun; 146(4):1795-807. PubMed ID: 17467916
[TBL] [Abstract][Full Text] [Related]
15. Acute stimulation of brain mu opioid receptors inhibits glucose-stimulated insulin secretion via sympathetic innervation.
Tudurí E; Beiroa D; Stegbauer J; Fernø J; López M; Diéguez C; Nogueiras R
Neuropharmacology; 2016 Nov; 110(Pt A):322-332. PubMed ID: 27511839
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of morphine analgesic effect with induction of mu-opioid receptor endocytosis in rats.
Hashimoto T; Saito Y; Yamada K; Hara N; Kirihara Y; Tsuchiya M
Anesthesiology; 2006 Sep; 105(3):574-80. PubMed ID: 16931992
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
18. Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Melkes B; Hejnova L; Novotny J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1289-1300. PubMed ID: 27600870
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Zhang F; Stevens DL; Beletskaya IO; Scoggins KL; Zhang Z; Gerk PM; Selley DE; Akbarali HI; Dewey WL; Zhang Y
J Med Chem; 2012 Nov; 55(22):10118-29. PubMed ID: 23116124
[TBL] [Abstract][Full Text] [Related]
20. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence.
Xu H; Partilla JS; Wang X; Rutherford JM; Tidgewell K; Prisinzano TE; Bohn LM; Rothman RB
Synapse; 2007 Mar; 61(3):166-75. PubMed ID: 17152090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]